| abstract |
Pharmaceutical hydrogel formulations containing polyvinyl alcohol are provided. The formulations may be provided as drug reservoirs in the electrotransport drug delivery system 10 or the manual transdermal system, or may be used in various other dosage forms, namely capsules, suppositories, aerosols, and the like. With these formulations, virtually no cineresis occurs during long term storage, and this advantage is derived by selecting the amount of polyvinyl alcohol in the gel corresponding to the degree of hydrolysis of the polymer. |